MedTrace Logo

Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

NCT00467584 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2014-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).

Conditions

Interventions

DRUG

High Dose Aspirin (1300 mg/day)

1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks

DRUG

Low Dose Aspirin (162 mg/day)

162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks

DRUG

Placebo

Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks

Sponsors & Collaborators

  • National Multiple Sclerosis Society

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Dean M. Wingerchuk, M.D., MSc · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467584 on ClinicalTrials.gov